Patents by Inventor Chia-Yu Huang
Chia-Yu Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210015829Abstract: The present invention provides compounds of Formula I: wherein X, R1, R2, R3 and R4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the TREX1 protein and thus can be used as medicaments for treating or preventing disorders affected by the inhibition of TREX1.Type: ApplicationFiled: October 6, 2020Publication date: January 21, 2021Applicant: Venenum Biodesign, LLCInventors: Jeffrey J. LETOURNEAU, Kiruthika SELVARANGAN ELAMPARUTHI, Chia-Yu HUANG, Venugopalareddy BOMMIREDDY VENKATA
-
Publication number: 20200317677Abstract: The present invention provides compounds of Formula I wherein X, R1, R2, R3 and R4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the TREX1 protein and thus can be used as medicaments for treating or preventing disorders affected by the inhibition of TREX1.Type: ApplicationFiled: March 25, 2020Publication date: October 8, 2020Inventors: Jeffrey J. Letourneau, Kiruthika Selvarangan Elamparuthi, Chia-Yu Huang, Venugopalareddy Bommireddy Venkata
-
Publication number: 20200308122Abstract: The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.Type: ApplicationFiled: June 29, 2017Publication date: October 1, 2020Applicant: Venenum Biodesign, LLCInventors: Chia-Yu Huang, Brian F. McGuinness, Dongchuan Shi, Steven G. Kultgen, Jeffrey J. Letourneau, James R. Beasley, Philip D. Stein, Andrew G. Cole
-
Patent number: 10654834Abstract: The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.Type: GrantFiled: June 29, 2017Date of Patent: May 19, 2020Assignee: Venenum Biodesign, LLCInventors: Chia-Yu Huang, Brian F. McGuinness, Xiaoqing Xu, Steven G. Kultgen, Ellen Sieber McMaster, James R. Beasley
-
Publication number: 20200131209Abstract: The present invention provides compounds of Formula I?: wherein , W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.Type: ApplicationFiled: October 24, 2019Publication date: April 30, 2020Inventors: David J. Diller, Axel Metzger, David E. Kaelin, JR., Steven Paget, Chia-Yu Huang, Brian F. Mcguinness, Audrey Julie Hospital, William Ronald Solvibile, JR.
-
Publication number: 20190330191Abstract: The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.Type: ApplicationFiled: June 29, 2017Publication date: October 31, 2019Applicant: Venenum Biodesign, LLCInventors: Chia-Yu Huang, Brian F. McGuinness, Xiaoqing Xu, Steven G. Kultgen, Ellen Sieber McMaster, James R. Beasley
-
Patent number: 8845500Abstract: A resistance adjustable rotational exerciser includes a body, two rotary members and an adjustment device. The body has two outer rings with a connection plate connected therebetween. The two rotary members are rotatably connected to the outer rings and each have a handle. The adjustment device has front and rear plates respectively connected to the front and rear sides of the connection plate. The front and rear plates have resistance strips. Springs are located between the connection plate and the front and rear plates. A knob is located at the front plate and connected to connection rods connected between the front and rear plates. The user holds the handles to operate the exerciser in different directions to exercise the muscles and joints. By operation of the knob, the distance between the front and rear plates is adjusted to obtain desired resistance.Type: GrantFiled: March 30, 2012Date of Patent: September 30, 2014Inventor: Chia-Yu Huang
-
Publication number: 20130260969Abstract: A resistance adjustable rotational exerciser includes a body, two rotary members and an adjustment device. The body has two outer rings with a connection plate connected therebetween. The two rotary members are rotatably connected to the outer rings and each have a handle. The adjustment device has front and rear plates respectively connected to the front and rear sides of the connection plate. The front and rear plates have resistance strips. Springs are located between the connection plate and the front and rear plates. A knob is located at the front plate and connected to connection rods connected between the front and rear plates. The user holds the handles to operate the exerciser in different directions to exercise the muscles and joints. By operation of the knob, the distance between the front and rear plates is adjusted to obtain desired resistance.Type: ApplicationFiled: March 30, 2012Publication date: October 3, 2013Inventor: Chia-Yu Huang
-
Patent number: 8513232Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.Type: GrantFiled: July 29, 2010Date of Patent: August 20, 2013Assignees: Cephalon, Inc., Pharmacopeia, LLCInventors: Edward R. Bacon, Nadine C. Becknell, Reddeppa reddy Dandu, Lisa Guise-Zawacki, Tao Guo, Chia-yu Huang, Robert L. Hudkins, Babu G. Sundar, Ming Tao, Minglang Wu, Allison L. Zulli
-
Patent number: 8501747Abstract: In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ÿ2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ÿ2C adrenergic receptors using such compounds or pharmaceutical compositions.Type: GrantFiled: February 11, 2008Date of Patent: August 6, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Manuel de lera Ruiz, Kevin D. McCormick, Christopher W. Boyce, Robert G. Aslanian, Younong Yu, Pietro Mangiaracina, Junying Zheng, Michael Y. Berlin, Stephanie Louise Ciesla, Chia-Yu Huang, Bo Liang
-
Patent number: 7985748Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.Type: GrantFiled: March 12, 2010Date of Patent: July 26, 2011Assignees: Pharmacopeia Drug Discovery, Inc., Scheeing CorporationInventors: Kevin D. McCormick, Christopher W. Boyce, Neng-Yang Shih, Robert G. Aslanian, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Purakkattle Biju, Chia-Yu Huang, Bo Liang, Ruiyan Liu, Rong-Qiang Liu, Lisa Guise-Zawacki
-
Publication number: 20110071131Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.Type: ApplicationFiled: July 29, 2010Publication date: March 24, 2011Applicants: CEPHALON, INC., PHARMACOPEIA, INC.Inventors: Edward R. Bacon, Nadine C. Becknell, Reddeppa reddy Dandu, Lisa Guise-Zawacki, Tao Guo, Chia-yu Huang, Robert L. Hudkins, Babu G. Sundar, Ming Tao, Minglang Wu, Allison L. Zulli
-
Patent number: 7803828Abstract: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.Type: GrantFiled: August 23, 2006Date of Patent: September 28, 2010Assignee: Schering-Plough CorporationInventors: Kevin D. McCormick, Christopher W. Boyce, Robert G. Aslanian, Neng-Yang Shih, Salem Fevrier, Pietro Mangiaracina, Chia-Yu Huang, Bo Liang, Rong-Qiang Liu, Huagang Lu
-
Publication number: 20100197562Abstract: In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ÿ2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ÿ2C adrenergic receptors using such compounds or pharmaceutical compositions.Type: ApplicationFiled: February 11, 2008Publication date: August 5, 2010Applicants: SCHERING CORPORATION AND PHARMACOPEIA, LLC, PHARMACOPEIA, INC.Inventors: Manuel De lera Ruiz, Kevin D. McCormick, Christopher W. Boyce, Robert G. Aslanian, Younong Yu, Pietro Mangiaracina, Junying Zheng, Michael Y. Berlin, Stephanie L. Ciesla, Chia-yu Huang, Bo Liang
-
Publication number: 20100173823Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.Type: ApplicationFiled: March 12, 2010Publication date: July 8, 2010Inventors: Kevin D. McCormick, Christopher W. Boyce, Neng-Yang Shih, Robert G. Aslanian, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Purakkattle Biju, Chia-Yu Huang, Bo Liang, Ruiyan Liu, Rong-Qiang Liu, Lisa Guise-Zawacki
-
Patent number: 7700592Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.Type: GrantFiled: February 13, 2007Date of Patent: April 20, 2010Assignee: Schering CorporationInventors: Kevin D. McCormick, Christopher W. Boyce, Neng-Yang Shih, Chia-Yu Huang, Robert G. Aslanian, Salem Fevrier, Bo Liang, Rong-qiang Liu, Ruiyan Liu, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Lisa Guise-Zawacki, Junying Zheng
-
Patent number: 7342016Abstract: Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.Type: GrantFiled: December 19, 2002Date of Patent: March 11, 2008Assignees: Schering Corporation, Pharmacopeia, Inc.Inventors: Hugh Y. Zhu, F. George Njoroge, Alan B. Cooper, Timothy J. Guzi, Dinanath F. Rane, Keith P. Minor, Ronald J. Doll, Viyyoor M. Girijavallabhan, Bama Santhanam, Patrick A. Pinto, Bancha Vibulbhan, Kartik M. Keertikar, Carmen S. Alvarez, John J. Baldwin, Ge Li, Chia-Yu Huang, Ray A. James, James J-S Wang, Jagdish A. Desai
-
Publication number: 20080039439Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.Type: ApplicationFiled: February 13, 2007Publication date: February 14, 2008Inventors: Kevin McCormick, Christopher Boyce, Neng-Yang Shih, Chia-Yu Huang, Robert Aslanian, Salem Fevrier, Bo Liang, Rong-qiang Liu, Ruiyan Liu, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Lisa Guise-Zawacki, Junying Zheng
-
Publication number: 20080027100Abstract: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.Type: ApplicationFiled: February 13, 2007Publication date: January 31, 2008Inventors: Kevin McCormick, Christopher Boyce, Neng-Yang Shih, Chia-Yu Huang, Robert Aslanian, Jianhua Chao, Salem Fevrier, Bo Liang, Huagang Lu, Pietro Mangiaracina, Rong-Qiang Liu, Younong Yu
-
Publication number: 20070299211Abstract: Self-polymerization of mono-aziridine (or azetidine) and multi-aziridine (or azetidine) containing compounds with vinyl group containing organic acid, such as acrylic acid (AA), 2-methylenesuccinic acid, 2,3-dimethylenesuccinic acid and etc, at ambient temperature results in the new type of cross-linked and linear type copolymers, respectively. The polymerization of multi-functional aziridine (or azetidine) containing compounds with vinyl group containing organic acid results in the formation of high cross-linked polymers. The self-polymerization takes place at ambient temperature and the resultants, cross-linked polymeric networked materials, are solvent insoluble and potential for adhesive, composite matrix and other applications. These insoluble materials are hydrolyzed in an acidic or basic condition to form the water soluble ?-amino acids.Type: ApplicationFiled: July 3, 2006Publication date: December 27, 2007Applicant: Tamkang UniversityInventors: Po-Cheng Chen, Shih-Chieh Wang, Chia-Yu Huang, Kan-Nan Chen